Tirzepatide (Mounjaro)

Key Messages

• Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
• The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
• This review assesses tirzepatide (Mounjaro), 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, and 15 mg/0.5 mL solution in a single-dose, prefilled pen, or vial for SC use.
• Indication: For once-weekly administration as an adjunct to diet and exercise to improve glycemic control for the treatment of adult patients with type 2 diabetes mellitus:
  • As monotherapy when metformin is inappropriate due to contraindication or intolerance
  • In combination with:
     metformin, or
     metformin and a sulfonylurea, or
     metformin and a sodium-glucose cotransporter 2 inhibitor, or
     basal insulin with or without metformin.